Cargando…
BRCA1: a movement toward cancer prevention
Breast cancer susceptibility gene 1 (BRCA1) was first identified in 1994 and has since been shown to encode a tumor suppressor protein that maintains genetic stability through DNA damage response pathways. Carriers of mutations in BRCA1 are predisposed to breast and ovarian cancer; however, their ca...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905290/ https://www.ncbi.nlm.nih.gov/pubmed/27308455 http://dx.doi.org/10.4161/23723556.2014.979685 |
_version_ | 1782437241198477312 |
---|---|
author | Alli, Elizabeth Ford, James M |
author_facet | Alli, Elizabeth Ford, James M |
author_sort | Alli, Elizabeth |
collection | PubMed |
description | Breast cancer susceptibility gene 1 (BRCA1) was first identified in 1994 and has since been shown to encode a tumor suppressor protein that maintains genetic stability through DNA damage response pathways. Carriers of mutations in BRCA1 are predisposed to breast and ovarian cancer; however, their cancers lack the targets for existing anticancer drugs. We describe a novel chemoprevention approach that uses DNA repair-activating agents to enhance the repair of oxidative DNA damage and, in turn, prevent tumorigenesis in the presence of mutant BRCA1. |
format | Online Article Text |
id | pubmed-4905290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49052902016-06-15 BRCA1: a movement toward cancer prevention Alli, Elizabeth Ford, James M Mol Cell Oncol Author's Views Breast cancer susceptibility gene 1 (BRCA1) was first identified in 1994 and has since been shown to encode a tumor suppressor protein that maintains genetic stability through DNA damage response pathways. Carriers of mutations in BRCA1 are predisposed to breast and ovarian cancer; however, their cancers lack the targets for existing anticancer drugs. We describe a novel chemoprevention approach that uses DNA repair-activating agents to enhance the repair of oxidative DNA damage and, in turn, prevent tumorigenesis in the presence of mutant BRCA1. Taylor & Francis 2015-01-21 /pmc/articles/PMC4905290/ /pubmed/27308455 http://dx.doi.org/10.4161/23723556.2014.979685 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Author's Views Alli, Elizabeth Ford, James M BRCA1: a movement toward cancer prevention |
title | BRCA1: a movement toward cancer prevention |
title_full | BRCA1: a movement toward cancer prevention |
title_fullStr | BRCA1: a movement toward cancer prevention |
title_full_unstemmed | BRCA1: a movement toward cancer prevention |
title_short | BRCA1: a movement toward cancer prevention |
title_sort | brca1: a movement toward cancer prevention |
topic | Author's Views |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905290/ https://www.ncbi.nlm.nih.gov/pubmed/27308455 http://dx.doi.org/10.4161/23723556.2014.979685 |
work_keys_str_mv | AT allielizabeth brca1amovementtowardcancerprevention AT fordjamesm brca1amovementtowardcancerprevention |